Prostate Cancer Immunotherapy: Where Do We Stand?
Prostate cancer is one of the most common cancers in men worldwide, but treatment progress has been slow compared to other cancers. Conventional treatments like surgery, radiation, and hormone therapy still form the mainstay of care. However, the emergence of immunotherapy has brought new hope, though results so far have been mixed.
Why Immunotherapy?
The immune system can identify and fight abnormal cancer cells, but prostate tumors are considered "cold" because they do not elicit strong immune responses. That is why checkpoint inhibitors like pembrolizumab have been less effective in this setting than in melanoma or lung cancer.
Current progress
Sipuleucel-T (Provenge): The only FDA-approved immunotherapy for prostate cancer, this dendritic cell-based vaccine improves survival in some men with advanced disease.
Checkpoint Inhibitors: Pembrolizumab is currently being tested in combination with PARP inhibitors and chemotherapy. Early signals are beneficial in specific subgroups.
CAR-T Therapy: Although still experimental, CAR-T cells are being engineered to target prostate-specific membrane antigen.
Cancer Vaccines: Novel vaccines like PROSTVAC are being studied to enhance T-cell activity.
The Road Ahead
To be effective in prostate cancer immunotherapy, researchers are combining checkpoint inhibitors with targeted therapies, vaccines, or hormonal agents. While we aren't there yet, the future looks promising.